A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato, at the forefront of discussions regarding remission rates in treatment-resistant depression (TRD). The analysis, spearheaded by Dr. Rakesh Jain, a clinical professor of psychiatry at Texas Tech University School of Medicine, Permian Basin, compiles remission data across six pivotal clinical trials, aiming to underscore the drug’s efficacy in achieving and maintaining remission for patients struggling with this often debilitating condition. This strategic move by J&J comes as Spravato continues its trajectory as a significant revenue generator, with sales reaching approximately $1.7 billion last year and Wall Street projecting an increase to $2.3 billion in 2026. The company is actively working to expand the drug’s market penetration by highlighting its clinical profile, particularly in the challenging landscape of TRD treatment.
The Historical Arc: From Anesthetic to Antidepressant Breakthrough
The journey of ketamine, the progenitor molecule of esketamine, spans more than six decades, originating in 1962 when Calvin Stevens first synthesized it at Parke-Davis. His initial quest was to discover a safer anesthetic, a goal ketamine effectively met for many years. However, over time, its unique pharmacological properties, particularly its rapid-acting antidepressant effects at sub-anesthetic doses, began to draw significant attention from the psychiatric community. This migration from the operating theatre to the psychiatric clinic represents a profound paradigm shift in mental health treatment.
Esketamine, specifically the S-enantiomer of the original ketamine compound, emerged as a more potent and refined therapeutic option. Its development culminated in a landmark approval by the U.S. Food and Drug Administration (FDA) in March 2019 for treatment-resistant depression, initially as an add-on therapy to conventional oral antidepressants. This approval was a pivotal moment, offering a novel mechanism of action for patients who had exhausted traditional treatment pathways. The evolution continued in January 2025, when regulators further cleared esketamine as the first and only monotherapy for TRD, signifying a broader recognition of its standalone therapeutic potential and expanding its utility in clinical practice.
The Landscape of Treatment-Resistant Depression: A Profound Unmet Need
The market for effective TRD treatments is substantial and continues to grow. According to the National Institute of Mental Health (NIMH), an estimated 21 million U.S. adults experienced at least one major depressive episode in 2021, accounting for 8.3% of the adult population. While many respond to initial antidepressant therapies, a significant subset faces persistent symptoms. Of the approximately 8.9 million U.S. adults receiving medication for major depression, roughly one-third—a staggering 2.8 million individuals—do not respond adequately to standard oral antidepressants. This failure to achieve a satisfactory response after trying at least two different antidepressant treatments at adequate doses and durations defines treatment-resistant depression.
As Dr. Rakesh Jain emphasizes, the human cost of TRD is immense: "There are millions upon millions of patients, some of them your friends and mine, some of them your family members, who are being treated for depression and are simply not in remission." This underscores the urgent need for innovative and effective therapies that can break the cycle of chronic depression and offer patients a path to sustained well-being.
Remission: The Gold Standard in Depression Treatment
The central theme of the J&J poster presentation and Dr. Jain’s advocacy is the concept of remission. In psychiatry, remission signifies not just an improvement in symptoms but a return to a state of near-normal functioning, where depressive symptoms are minimal or absent. This is a far more ambitious goal than mere "response," which often refers to a 50% reduction in symptoms but may still leave patients with significant residual impairment.
The poster reports remission rates based on the Montgomery-Åsberg Depression Rating Scale (MADRS), a widely used clinician-rated instrument that assesses 10 core depression symptoms, each scored from 0 to 6, for a total possible score of 0 to 60. Conventionally, a MADRS score of 10 or below indicates remission. Patients entering the trials reviewed in the analysis typically had baseline scores ranging from 29 to 38, placing them firmly in the moderate-to-severe depression category. Dr. Jain highlighted that the analysis even tightened the criteria for Spravato, assessing performance at a stricter MADRS score of 10 or below, rather than the slightly more lenient 12, demonstrating robust results even under rigorous conditions.
Achieving and sustaining remission is notoriously difficult, particularly in TRD. Dr. Jain notes that remission numbers are often absent from clinical trial reports for other augmentation strategies, such as atypical antipsychotics, because "The numbers look abysmal, or they don’t separate from placebo." He frequently references the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study, the largest real-world depression treatment trial ever conducted. This National Institute of Mental Health study enrolled over 4,000 outpatients with nonpsychotic major depression, sequencing them through up to four successive treatment steps. In the initial step, involving citalopram, approximately 28% of evaluable patients achieved remission (measured by HAM-D). However, by the third step, after two prior treatments had failed—the very definition of treatment resistance—the remission rate plummeted to a mere 13.7%. This stark drop underscores the profound challenge of achieving remission as treatment resistance increases, highlighting the critical need for more effective interventions.
Spravato’s Remission Data: A Multi-Trial Perspective
The J&J poster presented at Psych Congress Elevate provides a comprehensive overview of esketamine’s remission rates, drawing from six previously reported trials. These included two four-week, placebo-controlled studies (TRD4005, a monotherapy trial, and TRANSFORM-2, which paired esketamine with an oral antidepressant), one active-controlled trial comparing esketamine against quetiapine extended-release (ESCAPE-TRD), and three open-label extension studies that followed patients for up to 5.5 years (ESCAPE-LTE, SUSTAIN-2, and SUSTAIN-3).
The data showcased compelling results, particularly when juxtaposed against placebo. For Spravato monotherapy doses, remission (MADRS ≤10) at week 4 was reported at 13.9% and 21.5%, compared to 6.5% for placebo. In the TRANSFORM-2 study, Spravato plus an oral antidepressant achieved a 42.6% remission rate, significantly higher than the 24.0% seen with placebo plus an oral antidepressant.
The analysis also extended to long-term open-label extension studies, revealing the potential for durable remission. Remission rates (MADRS ≤10) were reported as 49.3% at approximately one year, 78.2% at about two and a half years, and 43.2% at the longest follow-up of around 5.5 years. Dr. Jain emphasized the breadth of this data, spanning different study designs, short-term and long-term outcomes, and even a comparative study, asserting that the analysis was not "cherry-picking" but offered a holistic view of esketamine’s performance.
It is important to note, however, that the poster explicitly labels this analysis as descriptive. It does not involve formal meta-analysis, pooled effect estimates, or statistical comparisons, and acknowledges trial-design differences that limit direct comparability. Nevertheless, for clinicians seeking a broad understanding of esketamine’s real-world potential, this compilation offers valuable insights.
Navigating the Nuances: Professional Scrutiny and Guideline Divergence
Despite the encouraging data presented, professional opinion on esketamine’s role in TRD treatment remains varied, and guideline bodies have adopted differing stances.
The strongest controlled evidence in the analysis comes from the ESCAPE-TRD trial, the only head-to-head comparison against an active comparator. Published in the New England Journal of Medicine, this study found that esketamine combined with an SSRI or SNRI produced a higher remission rate (27.1%) than quetiapine extended-release on the same backbone (17.6%) at week 8. Furthermore, esketamine patients were less likely to discontinue treatment due to safety or tolerability issues.
However, the magnitude of this advantage has been contested. The same trial reported a narrow gap in depression scores, with esketamine showing a 2.8-point advantage on the 60-point MADRS at week 8 and 2.2 points at week 32. The NEJM correspondence acknowledged that these differences fell below the smallest clinically meaningful threshold. Critiques published in the American Journal of Psychiatry further highlight these concerns. In a 2025 editorial, Baylor psychiatrists Sanjay Mathew and Nicholas Murphy questioned whether the Phase 3 program established the necessity of continuing treatment much beyond the first week, despite a near doubling of prescriptions after early 2023. Another systematic review by Fountoulakis, Saitis, and Schatzberg (AJP 2025) placed esketamine’s add-on effect sizes at weeks 2 to 4 at 0.15 to 0.23, comparable to the atypical antipsychotic augmentation strategies that Dr. Jain critiques, and found no significant antisuicidal benefit.
Guideline bodies reflect this spectrum of opinion. The 2022 VA/DoD depression guideline lists ketamine or esketamine as an augmentation option after several failed drug trials, but only as a "weak for" recommendation, resting on low-quality evidence and accompanied by explicit reservations about monitoring and feasibility. In the UK, the National Institute for Health and Care Excellence (NICE) went further in 2022, declining to recommend esketamine for routine NHS use. Their decision was based on insufficient clinical and economic evidence to support a reliable cost-effectiveness estimate, a ruling that predated the monotherapy approval. Conversely, Scotland’s medicines regulator had reached the opposite conclusion two years earlier, underscoring the ongoing debate.
Clarifying the Suicidal Ideation Indication
Beyond TRD, esketamine holds another FDA-approved indication: for major depressive disorder (MDD) with acute suicidal ideation or behavior. While this broad description might suggest direct anti-suicidal effects, Dr. Jain clarifies that the poster’s focus was on remission rates, not suicidality. Furthermore, the official FDA prescribing information is more circumscribed. It approves esketamine, in conjunction with an oral antidepressant, for the rapid reduction of depressive symptoms in these patients. Crucially, it explicitly states that "its effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated" and that "its use does not obviate the need for hospitalization if clinically warranted." This distinction is critical: the drug addresses the depressive symptoms in acutely suicidal patients, but the label makes no claim that it directly reduces suicidality itself.
Overcoming Clinical Inertia and Practical Roadblocks
Despite the data and the significant unmet need, the adoption of new psychiatric treatments, particularly those with unique administration requirements, can be slow. Dr. Jain acknowledges this inherent characteristic of the field: "Psychiatry is slow to change, it just is." He identifies clinician hesitation and a lack of comprehensive knowledge as major obstacles, precisely the gaps the recent poster aims to bridge.
The practical considerations for Spravato’s administration are also significant. It is dispensed only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program, implemented due to potential risks including sedation, dissociation, respiratory depression, and abuse potential. This mandates administration in a certified healthcare setting, followed by a monitoring period of at least two hours after every dose, and strict instructions against driving until the next day. These logistical requirements represent concrete frictions that can limit widespread access and adoption, even when clinicians recognize the drug’s potential.
Dr. Jain’s engagement with clinicians at the Psych Congress Elevate poster session revealed a common sentiment: "I didn’t get any pushback. On the contrary, the reaction was, ‘I really do need to start thinking about Spravato earlier and more often.’ And I told them, you’re right, that’s what the data compels us to do." This feedback suggests that robust data, presented clearly, can indeed begin to shift clinical perspectives and encourage earlier consideration of Spravato in the TRD treatment algorithm.
Future Implications and Outlook
The comprehensive data presented by Johnson & Johnson on Spravato’s remission rates represents a significant effort to solidify the drug’s position in the challenging landscape of treatment-resistant depression. As the prevalence of major depressive disorder remains high and a substantial portion of patients struggle with TRD, therapies offering a path to remission are critically important.
The ongoing discussions surrounding esketamine’s efficacy, cost-effectiveness, and real-world applicability will continue to shape its integration into clinical practice. While regulatory bodies and professional guidelines may evolve as more data emerges, J&J’s focus on demonstrating durable remission provides a compelling narrative for clinicians. The success of Spravato, both clinically and commercially, will depend on continued efforts to educate the medical community, address practical barriers to access, and foster a deeper understanding of its place in the evolving treatment paradigm for severe and resistant forms of depression. The journey of ketamine from an anesthetic to a potentially transformative antidepressant continues, with esketamine now firmly established as a key player in offering hope for millions seeking true remission.
